Ribosomal protein SA pseudogene 52 (RPSAP52)

Ribosomal protein SA pseudogene 52 (RPSAP52) is a long non-coding RNA recognized for its oncogenic properties across various human cancers. It is a transcribed pseudogene running antisense to HMGA2, influencing both nuclear and cytoplasmic gene regulation. RPSAP52 acts as a competing endogenous RNA, sequestering miRNAs to derepress oncogenes, and also interacts with RNA-binding proteins (notably IGF2BP2) to facilitate the translation of target mRNAs such as HMGA2 and LIN28B. Its overexpression leads to cancer cell proliferation, enhanced stemness, and poor clinical outcomes. Additionally, RPSAP52 may play a role in non-cancer diseases like renal failure by modulating gene expression under hypoxic conditions. RPSAP52 is being explored as a prognostic and diagnostic biomarker and as a candidate for experimental RNA-targeting therapies, but is not an established direct therapeutic target[1][2][3][5].

Other names

RPSAP52Ribosomal protein SA pseudogene 52

Not applicable for approved drugs. In research, antisense oligonucleotides (e.g., GapmeRs) have been used to knock down RPSAP52, leading to reduced tumor growth[5].